Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Last month, the U.S. Environmental Protection Agency (EPA) announced the draft Sixth Contaminant Candidate List (CCL 6) under the Safe Drinking Water Act (SDWA) and released it for public comment. CCL 6 identifies contaminants that are not yet regulated but are known or anticipated to occur in public water systems and may require future regulation. The draft list includes four contaminant groups — microplastics, pharmaceuticals, per‑ and polyfluoroalkyl substances (PFAS), and disinfection byproducts — along with 75 individual chemicals and nine microbes that may be found in drinking water. Although PFAS were included on prior lists, this is the first time the EPA has designated microplastics or pharmaceuticals as priority contaminant groups. Inclusion on the draft CCL 6 signals an emerging concern about these new contaminant groups and the potential for future regulatory action.
Under the SDWA, the EPA must publish a Contaminant Candidate List (CCL) every five years. Each CCL is a list of contaminants that:
The CCL is merely the first step in the SDWA regulatory process, but it serves as the main starting point for the EPA’s decision whether to regulate new contaminants. Contaminants identified on the list are prioritized for research, funding, and information collection to better understand health risks and treatment options. These contaminants may be further monitored under EPA’s Unregulated Contaminant Monitoring Rule (UCMR).
Once a CCL is finalized, the EPA uses it to monitor occurrence frequency (and therefore level of concern) and to make regulatory determinations.
For clients that design, manufacture, or market drinking water treatment technologies, the release of draft CCL 6 can be strategically important.
In short, CCL 6 is both a regulatory roadmap and a market signal. Clients in the drinking water treatment space should view this announcement as an opportunity to engage early in the regulatory development process. They should also consider aligning their product portfolios, R&D investments, and marketing materials with the contaminants EPA has now elevated as national priorities, particularly microplastics, pharmaceuticals, PFAS, and disinfection byproducts.
This just in
Firm Events
District Court vs. PTAB: Strategic Forum Selection in Life Sciences Patent Disputes
December 10, 2026 | 12:00 PM – 1:00 PM ET
Speaking Engagements
Performance on Trial: The Construction Manager’s Standard of Care Examined from All Angles
December 2, 2026 | 4:15 PM – 5:30 PM ET
The Hyatt Regency Huntington Beach
Huntington Beach, CA
Speaking Engagements
ACI’s 31st Annual Conference on Drug & Medical Device Litigation – 2026
December 2 – 3, 2026
New York Marriott Marquis
1535 Broadway, New York, NY 10036
Speaking Engagements
Entering the Defense Market: USA, Canada, Ukraine, UK, Germany, Poland
November 19, 2026 | 3:00 PM – 5:00 PM CT
Virtual